ALTAltimmune, Inc.同业对比
Altimmune, Inc. 与SIC 2834 行业的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 | 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALT本股 | $632M#8 | — | 1.3x#3 | 15419.1x#11 | 105.0%#5 | 7.3%#10 | -230461.0%#12 | -18.6%#8 | -21.1%#3 | — | -10.7%#7 | — |
| NVCT | $712M#1 | — | 78.4x#11 | — | — | -39.2%#12 | — | -291.1%#12 | — | — | — | — |
| ZVRA | $701M#2 | 12.7x#4 | 3.2x#7 | 6.6x#5 | 350.9%#2 | 178.9%#4 | -59.1%#5 | 38.2%#1 | — | — | — | — |
| NGNE | $695M#3 | — | 3.2x#6 | — | -100.0%#12 | -20.2%#11 | — | -41.6%#10 | — | — | — | — |
| IRWD | $690M#4 | 5.3x#2 | — | 2.3x#3 | -15.7%#8 | 2629.5%#1 | 33.3%#2 | — | 42.6%#1 | — | — | — |
| MNPR | $679M#5 | — | 5.2x#9 | — | — | 12.0%#9 | — | -10.5%#6 | — | — | — | — |
| VSTM | $665M#6 | — | 13.3x#10 | 21.5x#8 | 209.1%#4 | -60.3%#14 | -550.3%#9 | -419.1%#13 | — | — | -19.5%#8 | — |
| CBIO | $637M#7 | — | 3.9x#8 | 58.7x#9 | — | 306.4%#3 | -1407.5%#10 | 0.1%#4 | — | — | 37.1%#4 | — |
| PHAT | $622M#9 | — | — | 3.6x#4 | 216.9%#3 | 33.8%#8 | -91.4%#6 | — | — | 4#1 | -30.0%#9 | — |
| FBIOP | — | 6.7x#3 | — | — | 9.7%#6 | 76.2%#5 | -111.0%#7 | 22.5%#3 | — | — | 110.5%#2 | — |
| CRMD | $609M#10 | 3.6x#1 | 1.3x#2 | 2.0x#1 | 617.0%#1 | 1009.4%#2 | 48.2%#1 | 35.4%#2 | — | — | -32.5%#10 | — |
| AQST | $606M#11 | — | — | 13.6x#7 | -22.6%#9 | -89.8%#15 | -159.5%#8 | — | — | — | -0.8%#6 | — |
| CTMX | $602M#12 | — | 2.0x#4 | 7.9x#6 | -44.8%#10 | -154.5%#16 | -29.3%#3 | -5.7%#5 | -7.8%#2 | — | — | — |
| STTK | $589M#13 | — | 2.8x#5 | 589.1x#10 | -82.5%#11 | 35.3%#7 | -5150.8%#11 | -23.1%#9 | — | — | 175.6%#1 | — |
| ANNX | — | — | — | — | — | -49.6%#13 | — | -111.1%#11 | — | — | 48.7%#3 | — |
| ARVN | $534M#14 | 31.4x#5 | 0.9x#1 | 2.0x#2 | -0.3%#7 | 59.3%#6 | -45.1%#4 | -14.4%#7 | -25.3%#4 | — | 6.9%#5 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 本表构建超时,仅覆盖该组的一部分成员;排名仅相对于已列出的行,稍后会自动补全。 数据构建于 2026-09-16。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议